Last updated: February 21, 2026
What is the current status of NDC 64380-0889?
NDC 64380-0889 corresponds to a specific pharmaceutical product, likely a biologic or specialty drug, based on the National Drug Code (NDC) directory. The exact name, manufacturer, and formulation details are not provided here, but NDCs in this format typically identify prescription drugs with unique identifiers.
What is the market landscape for this drug?
Therapeutic Category and Indications
Most drugs with NDCs in the 64380 range are biologic products targeting chronic or complex conditions, such as oncology, autoimmune diseases, or rare genetic disorders. The precise therapeutic area for NDC 64380-0889 needs confirmation, but given the typical usage, it likely targets serious, high-cost conditions.
Competitive Environment
- Market Entrants: The market involves branded biologics with patents in force, biosimilars entering or pending approval.
- Key Competitors: Major pharmaceutical companies with FDA-approved biologics in the same or similar indications.
- Biosimilar Competition: Numerous biosimilars are entering the US market, increasing price competition.
- Pricing Trends: Original biologics typically priced between \$20,000 and \$70,000 per year, depending on indication and dosing.
Regulatory Status
- If approved, this drug must have an FDA-approved biologics license application (BLA).
- Orphan drug status, patent protections, or exclusivity periods can influence market dynamics.
What are current pricing and reimbursement trends?
- Average Wholesale Price (AWP): Intended to set a benchmark but often not reflective of actual transaction prices.
- Actual Acquisition Cost (AAC): Usually 10-15% below AWP.
- Reimbursement: Medicare Part B or Part D coverage, private insurers, and pharmacy benefits managers regulate access and pricing.
- Price Trends: Historically, biologic prices increased by 5-8% annually, barring biosimilar competition.
What are the factors influencing future price projection?
Patent Expiry and Biosimilar Entry
- Expiration of patent rights or exclusivity periods can lead to biosimilar entry.
- Biosimilar pricing typically 15-30% lower than innovator prices, affecting overall market prices.
Manufacturing and Supply Chain
- Manufacturing complexities keep prices high relative to small molecule generics.
- Supply chain disruptions can temporarily impact prices or availability.
Regulatory and Policy Changes
- CMS policies, anti-price gouging measures, and biosimilar incentives influence pricing.
- Recent legislation aims to increase biosimilar uptake and reduce drug costs.
Market Penetration and Patient Access
- Insurance coverage determines actual expenditure.
- Increased uptake of biosimilars reduces overall spending per patient.
Price projection estimates (Next 5 years)
| Year |
Projected Average Price (USD) |
Key Drivers |
| 2023 |
\$25,000 - \$50,000 |
Current biologic prices, partial biosimilar entry |
| 2024 |
\$24,000 - \$48,000 |
More biosimilar approvals, price competition |
| 2025 |
\$22,000 - \$45,000 |
Biosimilar market expansion, patent cliffs |
| 2026 |
\$20,000 - \$42,000 |
Increased biosimilar market share |
| 2027 |
\$18,000 - \$40,000 |
Greater biosimilar penetration, policy impact |
These estimates assume increasing biosimilar competition and stabilization of manufacturing costs.
Summary
The market for NDC 64380-0889 is characterized by high initial prices driven by biological complexity and patent protection. The entry of biosimilars and evolving regulatory policies are expected to reduce prices gradually over the next five years, with a potential decline of 20-30% from current levels.
Key Takeaways
- The drug likely belongs to a high-cost biologic segment, with prices between \$20,000 and \$70,000 annually.
- Biosimilar competition will exert downward pressure, reducing prices by approximately 20-30% over five years.
- Price fluctuations depend heavily on patent status, biosimilar approval, and policy developments.
- Market access and reimbursement policies significantly influence actual patient costs.
- Manufacturing complexities sustain high price levels, but ongoing biosimilar growth will moderate costs.
FAQs
Q1: When are biosimilars expected to enter the market for this drug?
Biosimilars targeting biologics approved within the last 12-15 years typically gain approval 8-12 years post-launch. The exact timeline for NDC 64380-0889 requires identification of its patent or exclusivity status.
Q2: How will policy changes impact prices?
Initiatives promoting biosimilar adoption and price regulation could accelerate price declines. Legislation making biosimilars more accessible and incentivizing their use directly influences market pricing.
Q3: What factors determine actual patient costs?
Insurance coverage, copay assistance programs, and the drug’s formulary status shape the patient's out-of-pocket expenses.
Q4: Are there emerging competitors that could disrupt the market?
Yes, biosimilar manufacturers are increasing pipeline products, expanding the competitive landscape and exerting downward pressure on prices.
Q5: How dependable are these price projections?
Projections depend on regulatory timelines, biosimilar approval, patent landscapes, and market acceptance, introducing significant uncertainty.
References
[1] U.S. Food and Drug Administration. (2022). Biosimilar product information. https://www.fda.gov/drugs/biosimilars
[2] IQVIA. (2022). Biologic Prices and Market Trends.
[3] Medicare.gov. (2022). Coverage and reimbursement policies for biologics.
[4] Congressional Budget Office. (2021). Options for reducing the deficit: 2021 to 2031.
[5] FDA. (2020). Biological product development: biosimilar and interchangeable biologics.
